The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCraneware Regulatory News (CRW)

Share Price Information for Craneware (CRW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,210.00
Bid: 2,200.00
Ask: 2,220.00
Change: -40.00 (-1.78%)
Spread: 20.00 (0.909%)
Open: 2,215.00
High: 2,215.00
Low: 2,210.00
Prev. Close: 2,250.00
CRW Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Significant Contract Win

8 Jan 2018 07:00

RNS Number : 1640B
Craneware plc
08 January 2018
 

Craneware plc

("Craneware", "the Group" or the "Company")

 

Trading Update and Significant Contract Win

 

8 January 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the six months ended 31 December 2017.

 

The Group is pleased to announce that it has continued to perform strongly in the first half of the financial year as it executes on its growth strategy. There has been strong underlying sales growth which has been extended by a significant new contract with one of the largest healthcare provider networks (the 'Network') in the US, further details provided below.

 

Renewals by dollar value have continued at over 100% in the period. In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from both new and renewal sales successes will be recognised over future periods, adding significantly to the Group's long term visibility of revenue under contract.

 

As a result, the Group expects to report increases in both revenue and adjusted EBITDA in the range of 15% to 18% for the six month period ended 31 December 2017, continuing the double digit growth delivered in the prior year.

The Group maintains healthy cash reserves of over $50m (H117: $45m) and has a further funding facility available from the Bank of Scotland of up to $50m. The Group continues to investigate opportunities to deploy these reserves.

 

With the growth in contracts signed in the period, continued sales momentum and high levels of revenue visibility, the Board is confident in meeting market expectations for the full year.

 

Significant Contract Win

This contract is expected to deliver in excess of $16m of revenue over its initial five year term as Craneware's Value Cycle solutions are utilised by over 75 new facilities across the Network. Having previously contracted to utilise Craneware's software in a small number of its hospitals, the customer carried out an assessment of the potential financial and operational impact Craneware's solution could bring to the entire Network. This has resulted in the roll out of Craneware's software across the Network with Craneware hosting the solution as part of the Network's strategic financial performance plans.

 

Notice of Results

The Company will announce results for the six months ended 31 December 2017 on 6 March 2018.

 

Keith Neilson, CEO of Craneware plc, commented, "These results, including a contract with one of the largest healthcare providers in the US, demonstrate the ongoing momentum we are experiencing in the business.

 

"The strength of our solutions and the value they deliver to all strata of customers, including large and complex health systems, allows us to support our customers as they address the challenges resulting from the continued evolution of the US Healthcare market. We are playing an increasingly strategic role in assisting healthcare providers as they look to improve and sustain their financial performance, whilst mitigating operational and compliance risks.

 

"These factors combined with our financial strength and high levels of visible revenue for future years, gives management confidence in its ongoing ability to deliver increasing stakeholder value this year and in the future."

For further information, please contact:

 

Craneware plc

Peel Hunt

Alma

+44 (0)131 550 3100

+44 (0)20 7418 8900

+44 (0)208 004 4217

Keith Neilson, CEO

Dan Webster

Caroline Forde

Craig Preston, CFO

Adrian Trimmings

George Sellar

Hilary Buchanan

Robyn Fisher

Josh Royston

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

About Craneware

 

Craneware enables healthcare providers to improve margins and enhance patient outcomes so they can continue to provide quality outcomes for all.

 

Craneware is the leader in automated value cycle solutions that help US Healthcare provider organisations discover, convert and optimise assets to achieve best clinical outcomes and financial performance. Founded in 1999, Craneware is headquartered in Edinburgh, Scotland with offices in Atlanta, Boston and Pittsburgh employing over 250 staff. Craneware's market-driven, SaaS solutions normalise disparate data sets, bringing in up-to-date regulatory and financial compliance data to deliver value at the points where clinical and operational data transform into financial transactions, creating actionable insights that enable informed tactical and strategic decisions. To learn more, visit craneware.com and thevaluecycle.com.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBIGDBUSGBGIR
Date   Source Headline
2nd Jun 20237:00 amRNSTransaction in Own Shares
1st Jun 20237:00 amRNSTransaction in Own Shares
31st May 20237:00 amRNSTransaction in Own Shares
30th May 20237:00 amRNSTransaction in Own Shares
26th May 20237:22 amRNSTransaction in Own Shares
25th May 20237:00 amRNSTransaction in Own Shares
24th May 20237:00 amRNSTransaction in Own Shares
23rd May 20237:00 amRNSTransaction in Own Shares
22nd May 20237:00 amRNSTransaction in Own Shares
19th May 20237:00 amRNSTransaction in Own Shares
18th May 20237:00 amRNSTransaction in Own Shares
17th May 20237:00 amRNSTransaction in Own Shares
16th May 20237:02 amRNSTransaction in Own Shares
12th May 20239:21 amRNSTransaction in Own Shares
11th May 20237:00 amRNSTransaction in Own Shares
5th May 202312:35 pmRNSNotification of Major Holdings
28th Apr 20237:00 amRNSTransaction in Own Shares
27th Apr 20237:00 amRNSTransaction in Own Shares
26th Apr 20237:00 amRNSTransaction in Own Shares
25th Apr 20237:00 amRNSTransaction in Own Shares
24th Apr 20237:00 amRNSTransaction in Own Shares
21st Apr 20237:00 amRNSTransaction in own shares
19th Apr 20237:00 amRNSTransaction in Own Shares
18th Apr 20237:00 amRNSTransaction in Own Shares
17th Apr 20237:00 amRNSTransaction in Own Shares
14th Apr 20237:00 amRNSBlock Listing Announcement
14th Apr 20237:00 amRNSTransaction in Own Shares
13th Apr 20237:18 amRNSTransaction in Own Shares
12th Apr 20237:00 amRNSShare Buyback Programme
24th Mar 202311:02 amRNSDividend Currency Election
14th Mar 20237:00 amRNSDirector Share Purchase
6th Mar 20237:00 amRNSInterim Results
13th Feb 20235:15 pmRNSHolding(s) in Company
1st Feb 20233:25 pmRNSDirector Share Purchase
27th Jan 20237:31 amRNSDirector Share Purchase
19th Jan 20232:05 pmRNSSecond Price Monitoring Extn
19th Jan 20232:00 pmRNSPrice Monitoring Extension
19th Jan 20237:00 amRNSTrading Update and Notice of Results
25th Nov 20222:14 pmRNSDividend Currency Election
25th Nov 20229:16 amRNSHolding(s) in Company
21st Nov 202211:40 amRNSGrant of Long Term Incentive Plan Awards
15th Nov 20222:25 pmRNSResult of AGM
15th Nov 20227:00 amRNSAGM Statement and Board Appointment
4th Nov 20221:33 pmRNSHolding(s) in Company
14th Oct 20225:22 pmRNSPosting of Annual Report and Notice of AGM
14th Oct 20227:00 amRNSBlock listing Interim Review
11th Oct 20224:19 pmRNSHolding(s) in Company
10th Oct 202211:10 amRNSHolding(s) in Company
10th Oct 202211:02 amRNSHolding(s) in Company
23rd Sep 20229:06 amRNSVesting of Long Term Incentive Plan Awards

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.